Considering previous in vitro results and the targets reported for the two anti-leukemia drugs used as positive controls, we decided to study five potential pharmacological receptors associated to cancer: topoisomerase IIα (TIIα), topoisomerase IIβ(TIIβ) dihydrofolate reductase (DHFR), methylenetetrahydrofolate dehydrogenase (MTHFD), and Bcl-2-related protein A1 (BCL-2) [17,18,19]. The gene discussed is DHFR; the disease is leukemia.